July 31, 2012
/PRNewswire/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the second quarter ended
June 30, 2012
Tuesday, August 7, 2012
before the markets open. The announcement will be followed by a live webcast and conference call at
8:30 a.m. Eastern time
5:30 a.m. Pacific time
Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (888) 771-4371 (domestic) or (847) 585-4405 (international), participant code 33012560. The webcast can be accessed live on the investor relations section of the Orexigen web site at
and will be archived for 14 days following the call.
About Orexigen Therapeutics
Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company's lead product candidate is Contrave, which has completed Phase III clinical trials and for which a New Drug Application has been submitted and reviewed by the FDA. The Company has also reached agreement with the FDA on a Special Protocol Assessment (SPA) for the Light Study, the Contrave cardiovascular outcomes trial. The Company's other product candidate, Empatic™, has completed Phase II clinical trials. Further information about the Company can be found at
Vice President, Corporate Communications & Business Development858-875-8600
SOURCE Orexigen Therapeutics, Inc.